Recent News About Public Citizen Litigation Group View More
WASHINGTON (Legal Newsline) – Two nonprofit, public-interest research, litigation and advocacy organizations allege a federal agency has unlawfully failed to respond to its petition concerning a bulk drug substance.
Last week, more than 150 groups and organizations sent a letter to members of the U.S. Senate Judiciary Committee, urging them to oppose any “ill-considered efforts” that would split the U.S. Court of Appeals for the Ninth Circuit. So far, three such bills have been introduced in Congress this year.
The groups take issue with President Donald Trump’s Jan. 30 order, “Reducing Regulation and Controlling Regulatory Costs,” which calls for rescinding two government regulations for every new rule introduced, along with interim guidance issued by the Office of Management and Budget, or OMB, Feb. 2.
Groups representing businesses and financial industries contend a ban would make way for plaintiffs’ lawyers and hurt the economy. They want to see more research done before the Consumer Financial Protection Bureau starts the rulemaking process.